Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)

被引：3
|
作者：
Mooradian, M. [1 ,2 ]
Allen, A. [3 ]
Cai, L. [3 ]
Xiao, Y. [3 ]
Chander, P. [3 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116P
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [31] Pacific-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with Durvalumab after chemoradiotherapy
    Christoph, D. C.
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    McDonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Haakensen, Drageset, V
    Bar, J.
    Chouaid, C.
    Bray, V
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 53
  • [32] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
    Cortiula, Francesco
    De Ruysscher, Dirk
    Steens, Michelle
    Wijsman, Robin
    van der Wekken, Anthonie
    Alberti, Martina
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178
  • [33] Real-world analysis of treatment patterns and efficacy of durvalumab maintenance after chemoradiotherapy in NSCLC patients
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Ruehle, A.
    Tufman, A.
    Reinmuth, N.
    Duell, T. H-G-F.
    Belka, C.
    Manapov, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S742 - S742
  • [34] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
    Bischoff, Helge
    Garassino, Marina Chiara
    Mazieres, Julien
    Reck, Martin
    Chouaid, Christos
    Cove-Smith, Laura
    Mansy, Talal
    Migliorino, Maria R.
    Delmonte, Angelo
    Garcia Sanchez, Jose
    Chara Velarde, Luis Enrique
    Bernabe, Reyes
    Paz-Ares, Luis
    Perez, Ignacio Diaz
    Trunova, Nataliya
    Foroutanpour, Kayhan
    Faivre-Finn, Corinne
    Reinmuth, Niels
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 160 - 161
  • [35] Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)
    Garassino, M. C.
    Mazieres, J.
    Reck, M.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L.
    Mansy, T.
    Cortinovis, D.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. Garcia
    Velarde, L. E. Chara
    Bernabe, R.
    Paz-Ares, L.
    Perez, I. Diaz
    Trunova, N.
    Foroutanpour, K.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S81 - S82
  • [36] Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
    Zukin, Mauro
    Gondim, Victor
    Shimada, Andrea Kazumi
    Lima, Ellias Magalhaes e Abreu
    Mathias, Clarissa
    Barra, Williams Fernandes
    William Jr, William Nassib
    Padoan, Monica
    Bittencourt, Yuri
    Yamamura, Rosely
    Silva, Carlos Eduardo Baston
    Rossato, Leticia de Jesus
    Monteiro, Caio de Almeida
    Jesus, Rafaela Gomes de
    Gossling, Gustavo
    Gelatti, Ana Caroline Zimmer
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2024, 50 (06)
  • [37] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
    Faivre-Finn, Corinne
    Spigel, David R.
    Senan, Suresh
    Langer, Corey
    Perez, Bradford A.
    Ozguroglu, Mustafa
    Daniel, Davey
    Villegas, Augusto
    Vicente, David
    Hui, Rina
    Murakami, Shuji
    Paz-Ares, Luis
    Broadhurst, Helen
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott J.
    LUNG CANCER, 2021, 151 : 30 - 38
  • [38] Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC
    Kuang, S.
    Liu, M.
    Ho, C.
    Berthelet, E.
    Laskin, J.
    Sun, S.
    Zhang, T.
    Melosky, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S807 - S808
  • [39] Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
    Girard, Nicolas
    Bar, Jair
    Garrido, Pilar
    Garassino, Marina C.
    McDonald, Fiona
    Mornex, Francoise
    Filippi, Andrea R.
    Smit, Hans J. M.
    Peters, Solange
    Field, John K.
    Christoph, Daniel C.
    Sibille, Anne
    Fietkau, Rainer
    Haakensen, Vilde D.
    Chouaid, Christos
    Markman, Ben
    Hiltermann, T. Jeroen N.
    Taus, Alvaro
    Sawyer, William
    Allen, Allison
    Chander, Pratibha
    Licour, Muriel
    Solomon, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (02) : 181 - 193
  • [40] Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
    Patel, S.
    Zhao, S.
    Wei, L.
    Li, M.
    Bertino, E.
    Presley, C.
    Welliver, M.
    Haglund, K.
    Palmer, J.
    Arnett, A.
    Beyer, S.
    Mende, E.
    Elder, J.
    Hardesty, D.
    Shields, P.
    Carbone, D.
    Otterson, G.
    Williams, T.
    Owen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S363 - S364
12345